(FMS) Fresenius Medical Care - Ratings and Ratios
Exchange: NYSE • Country: Germany • Currency: USD • Type: Common Stock • ISIN: US3580291066
FMS: Dialyzers, Machines, Solutions, Medications, Equipment, Supplies
Fresenius Medical Care AG (NYSE:FMS) stands as a global leader in renal care, offering a comprehensive suite of dialysis services and products. The companys extensive network spans Germany, North America, and international markets, providing critical care for patients with renal diseases.
Their services encompass outpatient dialysis clinics, where they deliver treatment along with essential laboratory and diagnostic support. Additionally, Fresenius offers materials, training, and patient support, including home delivery of supplies and follow-up assistance. In the U.S., they provide dialysis services under contract to hospitals for patients with end-stage renal disease (ESRD) and acute kidney failure.
As a manufacturer, Fresenius produces a wide array of healthcare products, including polysulfone dialyzers, hemodialysis machines, and peritoneal dialysis solutions. Their portfolio also extends to water treatment systems and apheresis products, showcasing their commitment to innovation in renal care.
The companys distribution strategy is multifaceted, selling directly to clinics and hospitals while also utilizing local sales forces, distributors, and agents. This approach ensures their products and services reach a broad audience, supporting both home and clinical settings.
Fresenius Medical Care AG, established in 1996 and headquartered in Bad Homburg, Germany, is a significant player in the healthcare services sector. Their financial metrics, including a market cap of $14.348B and a P/E ratio of 20.81, highlight their stability and growth potential in the industry.
For investors, Fresenius offers a unique blend of steady cash flows from its services and growth opportunities through its product innovations. Their diversified revenue streams and global presence make them a resilient player in the healthcare market, providing a compelling option for those seeking exposure to the growing renal care sector.
Additional Sources for FMS Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
FMS Stock Overview
Market Cap in USD | 14,072m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 1996-09-19 |
FMS Stock Ratings
Growth 5y | -14.7% |
Fundamental | 4.48% |
Dividend | 30.1% |
Rel. Strength Industry | 19 |
Analysts | 3.17/5 |
Fair Price Momentum | 22.29 USD |
Fair Price DCF | 77.16 USD |
FMS Dividends
Dividend Yield 12m | 2.88% |
Yield on Cost 5y | 2.27% |
Annual Growth 5y | -2.16% |
Payout Consistency | 96.9% |
FMS Growth Ratios
Growth Correlation 3m | 37.6% |
Growth Correlation 12m | 77.6% |
Growth Correlation 5y | -72.9% |
CAGR 5y | -3.68% |
CAGR/Max DD 5y | -0.05 |
Sharpe Ratio 12m | 0.47 |
Alpha | 12.13 |
Beta | 0.60 |
Volatility | 28.68% |
Current Volume | 362.8k |
Average Volume 20d | 355.9k |
As of March 14, 2025, the stock is trading at USD 23.17 with a total of 362,837 shares traded.
Over the past week, the price has changed by -1.66%, over one month by -4.45%, over three months by -2.03% and over the past year by +18.75%.
Neither. Based on ValueRay Fundamental Analyses, Fresenius Medical Care is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 4.48 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of FMS as of March 2025 is 22.29. This means that FMS is currently overvalued and has a potential downside of -3.8%.
Fresenius Medical Care has received a consensus analysts rating of 3.17. Therefor, it is recommend to hold FMS.
- Strong Buy: 1
- Buy: 1
- Hold: 3
- Sell: 0
- Strong Sell: 1
According to ValueRays Forecast Model, FMS Fresenius Medical Care will be worth about 24.2 in March 2026. The stock is currently trading at 23.17. This means that the stock has a potential upside of +4.27%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 26.7 | 15.1% |
Analysts Target Price | 23.5 | 1.2% |
ValueRay Target Price | 24.2 | 4.3% |